MedPath

Ceftazidime

Ceftazidime for Injection, USP

Approved
Approval ID

aec64360-8452-4987-a366-a5a4f8762ab6

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 3, 2024

Manufacturers
FDA

Sagent Pharmaceuticals

DUNS: 080579617

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ceftazidime

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code25021-129
Application NumberANDA062640
Product Classification
M
Marketing Category
C73584
G
Generic Name
ceftazidime
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateJanuary 3, 2024
FDA Product Classification

INGREDIENTS (2)

sodium carbonateInactive
Code: 45P3261C7T
Classification: IACT
ceftazidimeActive
Quantity: 6 g in 30 mL
Code: 9M416Z9QNR
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ceftazidime - FDA Drug Approval Details